We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
Read MoreHide Full Article
Paratek Pharmaceuticals, Inc. announced that the FDA has granted an Orphan Drug designation to its sole marketed drug, Nuzyra (omadacycline), for the treatment of infections caused by Nontuberculous Mycobacteria (“NTM”).
The Orphan Drug designation is granted to drugs that are capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses, an exemption from the FDA user fee and marketing exclusivity upon potential approval.
Per the press release, the above Orphan Drug tag includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), for which a phase IIb study on Nuzyra is currently ongoing.
The placebo-controlled phase IIb study is evaluating Nuzyra monotherapy for treating patients with M. abscessus pulmonary disease who are in the early phase of treatment and are not taking other antibiotics. The primary endpoints of the study are to check the improvement in symptoms, and safety and tolerability following 12 weeks of treatment.
Per the company, pulmonary infections caused by M. abscessus affect around 11,500 patients in the United States. Currently, there is no FDA-approved antibiotic therapy for the indication. Hence, if successfully developed and upon potential approval, Nuzyra can provide a new treatment option for the given patient population.
Shares of Paratek have plunged 16.8% so far this year compared with the industry’s decrease of 0.2%.
Image Source: Zacks Investment Research
We remind investors that Nuzyra is currently marketed as a once-daily antibiotic with both oral and intravenous formulations, for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Nuzyra generated sales worth $66 million in the first half of 2021, reflecting a significant increase year over year. Potential label expansions to treat other indication will boost the drug’s sales in the days ahead.
We note that, in 2019, the Biomedical Advanced Research and Development Authority (“BARDA”) awarded a contract to Paratek for up to $284.5 million to support the development and manufacturing of Nuzyra in the United States for the treatment of pulmonary anthrax. During the second quarter of 2021, the BARDA accepted the first procurement of Nuzyra, valued at $37.9 million.
Repligen’s earnings estimates have been revised 22.1% upward for 2021 and 17.9% upward for 2022 over the past 60 days. The stock has surged 32.9% year to date.
Corvus Pharmaceuticals’ loss per share estimates have narrowed 24.4% for 2021 and 21.4% for 2022, over the past 60 days.
Vertex’s earnings estimates have been revised 10.2% upward for 2021 and 6.4% upward for 2022 over the past 60 days.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
Paratek Pharmaceuticals, Inc. announced that the FDA has granted an Orphan Drug designation to its sole marketed drug, Nuzyra (omadacycline), for the treatment of infections caused by Nontuberculous Mycobacteria (“NTM”).
The Orphan Drug designation is granted to drugs that are capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses, an exemption from the FDA user fee and marketing exclusivity upon potential approval.
Per the press release, the above Orphan Drug tag includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), for which a phase IIb study on Nuzyra is currently ongoing.
The placebo-controlled phase IIb study is evaluating Nuzyra monotherapy for treating patients with M. abscessus pulmonary disease who are in the early phase of treatment and are not taking other antibiotics. The primary endpoints of the study are to check the improvement in symptoms, and safety and tolerability following 12 weeks of treatment.
Per the company, pulmonary infections caused by M. abscessus affect around 11,500 patients in the United States. Currently, there is no FDA-approved antibiotic therapy for the indication. Hence, if successfully developed and upon potential approval, Nuzyra can provide a new treatment option for the given patient population.
Shares of Paratek have plunged 16.8% so far this year compared with the industry’s decrease of 0.2%.
Image Source: Zacks Investment Research
We remind investors that Nuzyra is currently marketed as a once-daily antibiotic with both oral and intravenous formulations, for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Nuzyra generated sales worth $66 million in the first half of 2021, reflecting a significant increase year over year. Potential label expansions to treat other indication will boost the drug’s sales in the days ahead.
We note that, in 2019, the Biomedical Advanced Research and Development Authority (“BARDA”) awarded a contract to Paratek for up to $284.5 million to support the development and manufacturing of Nuzyra in the United States for the treatment of pulmonary anthrax. During the second quarter of 2021, the BARDA accepted the first procurement of Nuzyra, valued at $37.9 million.
Zacks Rank & Stocks to Consider
Paratek currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Repligen Corporation (RGEN - Free Report) , Corvus Pharmaceuticals, Inc. (CRVS - Free Report) and Vertex Pharmaceuticals Incorporated (VRTX - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’s earnings estimates have been revised 22.1% upward for 2021 and 17.9% upward for 2022 over the past 60 days. The stock has surged 32.9% year to date.
Corvus Pharmaceuticals’ loss per share estimates have narrowed 24.4% for 2021 and 21.4% for 2022, over the past 60 days.
Vertex’s earnings estimates have been revised 10.2% upward for 2021 and 6.4% upward for 2022 over the past 60 days.